Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 2/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420110 | 1.00 | MAOA (0.41) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL7197365 | 1.00 | MAOA (0.41) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL9209 | 1.00 | MAOA (0.41) | MAOAMAOBLMNACRHBPCRHR2 | |
| Water SCHEMBL1552056 | 0.98 | MAOA (0.39) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL151338 | 0.98 | MAOA (0.39) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL2143603 | 0.98 | MAOA (0.39) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL7836619 | 0.98 | MAOA (0.39) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL9249037 | 0.98 | MAOA (0.39) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL39996 | 0.98 | MAOA (0.39) | MAOAMAOBLMNACRHBPCRHR2 | |
| SCHEMBL887939 | 0.98 | MAOA (0.39) | MAOAMAOBLMNACRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025022038-A1 | NEW COMPOUNDS DERIVED FROM MORIN, METHOD FOR OBTAINING THEM AND THEIR USES | UNIVERSIDAD DE SEVILLA (ES) | 2025-01-30 | — | — | WO | claimed |
| EP-4486395-A1 | PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE | Atoms for Cure GmbH (DE) | 2025-01-08 | — | — | EP | claimed |
| EP-4452326-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2024-10-30 | — | — | EP | claimed |
| CN-117624162-A | Flavonol derivative containing triazolopyridine and preparation method and application thereof | 贵州大学 | 2024-03-01 | — | — | CN | claimed |
| WO-2023165987-A1 | PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE | Atoms for Cure GmbH (DE) | 2023-09-07 | — | — | WO | claimed |
| WO-2023118195-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2023-06-29 | — | — | WO | claimed |
| US-20230064951-A1 | PRODRUGS, ANALOGS OR DERIVATIVES OF KAEMPFEROL AS ANTIVIRAL AGENTS | Sanctum Therapeutics Corporation | 2023-03-02 | — | — | US | claimed |
| CN-114555104-A | Herbal preparation for stimulating hair growth, controlling hair loss, dandruff and infections thereof using ageratum species | GE营养有限公司 | 2022-05-27 | — | — | CN | claimed |
| EP-3807880-B1 | METHOD FOR PRODUCING AN ELECTRONIC COMPONENT WHICH INCLUDES A SELF-ASSEMBLED MONOLAYER | MERCK PATENT GMBH (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4638424-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119504756-A | Condensed-cyclic compound and use thereof | 轩竹生物科技股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119497709-A | Pyrimidine derivatives | ASKA 制药株式会社 | 2025-02-21 | — | — | CN | disclosed |
| WO-2025022038-A1 | NEW COMPOUNDS DERIVED FROM MORIN, METHOD FOR OBTAINING THEM AND THEIR USES | UNIVERSIDAD DE SEVILLA (ES) | 2025-01-30 | — | — | WO | disclosed |
| WO-2022157277-A1 | PRECURSOR MARKER AND RADIOTRACER FOR NUCLEAR-MEDICAL DIAGNOSIS AND THERAPY OF BONE-METASTATIC PROSTATE CANCER | SCV - SpezialChemikalienVertrieb GmbH (DE) | 2022-07-28 | — | — | WO | disclosed |
| CN-114555104-A | Herbal preparation for stimulating hair growth, controlling hair loss, dandruff and infections thereof using ageratum species | GE营养有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022075382-A1 | ESTER COMPOUND AND RESIN COMPOSITION | 味の素株式会社 | 2022-04-14 | — | — | WO | disclosed |
| WO-2022075383-A1 | ESTER COMPOUND AND RESIN COMPOSITION | 味の素株式会社 | 2022-04-14 | — | — | WO | disclosed |
| CN-109503686-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064951-A1 | PRODRUGS, ANALOGS OR DERIVATIVES OF KAEMPFEROL AS ANTIVIRAL AGENTS | ACE2, ACE, SARS1 | MAOA 4096/4885MAOB 4279/4885LMNA 4225/4885 |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | MAOA 4437/4885MAOB 4259/4885LMNA 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.